Pharmacogenetics in the cancer clinic: from candidate gene studies to next-generation sequencing.
Genetics has significantly added to our understanding of variability in drug response, especially in cancer treatment. Pharmacogenetics, aimed at predicting a patient's chance for effective and safe drug treatment by interrogating germ line genetic variants, has moved from investigating a monogenetic candidate gene to examining complex phenotype-based genome-wide approaches. With the rapid advances in sequencing technologies, decline in costs, and swift turnaround times, large-scale genomic information will become available in the clinical setting, facilitating implementation of pharmacogenetics.
Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands;
H-J
HJ
Guchelaar
Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands;
H
H
Gelderblom
Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands;
T
T
van der Straaten
1] Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands; [2] Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
J H M
JH
Schellens
Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands;
J J
JJ
Swen
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D014644:Genetic Variation; D055106:Genome-Wide Association Study / Q000379:methods; D023281:Genomics; D059014:High-Throughput Nucleotide Sequencing; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics; D010597:Pharmacogenetics / Q000379:methods*; D010641:Phenotype
D000970:Antineoplastic Agents